Skip to content

Scholar Rock SRRK Foreign currency translation gains (losses)

Foreign currency translation gains (losses) at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$990K+348%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$1.78M+89,300%
Cytokinetics logo
CytokineticsCYTK
-$404K-29.5%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$32K-178%
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's foreign currency translation gains (losses).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's foreign currency translation gains (losses)?
Scholar Rock (SRRK) reported foreign currency translation gains (losses) of $667K in Q1 2026.
How has Scholar Rock's foreign currency translation gains (losses) changed year-over-year?
Scholar Rock's foreign currency translation gains (losses) increased by 133500.0% year-over-year, from -$500 to $667K.
What does foreign currency translation gains (losses) mean?
This metric captures the gains or losses resulting from the translation of financial statements of foreign subsidiaries or transactions denominated in currencies other than the company's functional currency. It reflects the impact of exchange rate volatility on the company's reported financial position. This is essential for evaluating how global operations or international supply chain exposures affect overall financial performance.